Wave Life Sciences Ltd
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
WVE$3.41-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(126,261) | $(41,257) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Amortization of right-of-use assets | 3,518 | 3,105 |
| Depreciation of property and equipment | 2,989 | 3,919 |
| Share-based compensation expense | 9,897 | 7,443 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 21,086 | (7,000) |
| Prepaid expenses | (660) | 418 |
| Other assets | 989 | (2,101) |
| Accounts payable | (39) | (3,953) |
| Accrued expenses and other current liabilities | (2,686) | (4,928) |
| Deferred revenue | (11,263) | 62,299 |
| Operating lease liabilities | (4,948) | (3,947) |
| Other non-current liabilities | — | (190) |
| Net cash provided by (used in) operating activities | (107,378) | 13,808 |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (852) | (759) |
| Net cash used in investing activities | (852) | (759) |
| Cash flows from financing activities | ||
| Proceeds from the issuance of ordinary shares as a part of the December 2023 Offering, net of offering costs | 14,038 | — |
| Proceeds from the issuance of ordinary shares as a part of the September 2024 Offering, net of offering costs | 173,900 | — |
| Proceeds from the issuance of pre-funded warrants as a part of the September 2024 Offering, net of offering costs | 14,100 | — |
| Proceeds from the issuance of ordinary shares pursuant to the GSK Collaboration Agreement | — | 34,623 |
| Proceeds from issuance of ordinary share pursuant to the “at-the-market” equity program, net of offering costs | 15,293 | 3,080 |
| Proceeds from the exercise of share options | 919 | 121 |
| Proceeds from the ESPP | 659 | 748 |
| Net cash provided by financing activities | 218,909 | 38,572 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | (35) | (153) |
| Net increase in cash, cash equivalents, and restricted cash | 110,644 | 51,468 |
| Cash, cash equivalents, and restricted cash, beginning of period | 204,050 | 92,157 |
| Cash, cash equivalents, and restricted cash, end of period | $314,694 | $143,625 |
| Supplemental disclosure of cash flow information | ||
| Offering costs related to the September 2024 Offering in accrued expenses at period end | $500 | $— |
Wave Life Sciences Ltd.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.